Ring Therapeutics cuts workforce in latest round of layoffs as CEO departsnews2024-12-18T14:58:47+00:00December 18th, 2024|Endpoints News|
Shinobi adds Borges as science chief, Katz as top medical officernews2024-12-17T11:00:56+00:00December 17th, 2024|Endpoints News|
Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio reviewnews2024-12-16T11:45:07+00:00December 16th, 2024|Endpoints News|
Roche terminates a Phase 3 Spark gene therapy in hemophilia Anews2024-12-16T11:20:45+00:00December 16th, 2024|Endpoints News|
Editas to cut 65% of workforce, officially stops work on ex vivo sickle cell therapynews2024-12-12T22:09:20+00:00December 12th, 2024|Endpoints News|
Genetic medicine startups Chroma, Nvelop merge into nChromanews2024-12-11T12:00:50+00:00December 11th, 2024|Endpoints News|
#ASH24: Arcellx and Gilead seek to unseat J&J/Legend in multiple myelomanews2024-12-10T02:28:02+00:00December 10th, 2024|Endpoints News|
#ASH24: Beam shares results from seven patients who received gene-edited sickle cell therapynews2024-12-09T03:10:43+00:00December 9th, 2024|Endpoints News|
FDA is looking into hematology risks after patients take Bluebird’s Skysona gene therapynews2024-11-27T19:44:30+00:00November 27th, 2024|Endpoints News|
Updated: Roche buys out CAR-T partner Poseida for $1B upfrontnews2024-11-26T11:41:03+00:00November 26th, 2024|Endpoints News|
